- Home
- RIGL vs BLDP Comparison
RIGL vs BLDP Comparison
Compare RIGL & BLDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | BLDP |
|---|---|---|
| Founded | 1996 | 1979 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.4M | 700.7M |
| IPO Year | 2000 | 2009 |
Fundamental Metrics
Financial Performance| Metric | RIGL | BLDP |
|---|---|---|
| Price | $34.56 | $2.15 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 5 | 7 |
| Target Price | ★ $43.20 | $2.24 |
| AVG Volume (30 Days) | 257.9K | ★ 2.1M |
| Earning Date | 04-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 807.14 | N/A |
| EPS | ★ 5.38 | N/A |
| Revenue | ★ $179,278,000.00 | N/A |
| Revenue This Year | $66.81 | $41.72 |
| Revenue Next Year | N/A | $13.99 |
| P/E Ratio | $6.66 | ★ N/A |
| Revenue Growth | ★ 53.38 | N/A |
| 52 Week Low | $15.50 | $1.00 |
| 52 Week High | $52.24 | $4.10 |
Technical Indicators
Market Signals| Indicator | RIGL | BLDP |
|---|---|---|
| Relative Strength Index (RSI) | 44.17 | 38.73 |
| Support Level | $33.05 | $2.03 |
| Resistance Level | $36.95 | $2.28 |
| Average True Range (ATR) | 1.46 | 0.09 |
| MACD | 0.24 | 0.02 |
| Stochastic Oscillator | 39.78 | 52.63 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About BLDP Ballard Power Systems Inc.
Ballard Power Systems Inc is engaged in design, development, manufacture, sale and service of proton exchange membrane ("PEM") fuel cell products for a variety of applications, focusing on power products for bus, truck, rail, marine, stationary and emerging market (material handling, off-road and other) applications, as well as the delivery of services, including technology solutions, after sales services and training. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. Key geographical revenue is derived from Poland followed by United States, United Kingdom, and other countries.